Picture of Immutep logo

IMM — Immutep Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-17.79%
3m-32.37%
6m-15.41%
1yr-10.81%
Volume Change (%)
10d/3m-17.24%
Price vs... (%)
52w High-47.59%
50d MA-21.67%
200d MA-27.12%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-27.02%
Return on Equity-56.12%
Operating Margin-4955.57%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Immutep EPS forecast chart

Profile Summary

Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

Directors

Last Annual
June 30th, 2021
Last Interim
June 30th, 2021
Incorporated
May 21st, 1987
Public Since
June 23rd, 1988
No. of Shareholders
13,045
No. of Employees
19
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
748,152,935

IMM Share Price Performance

FAQ

Or unlock with your email

Or unlock with your email